Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Big COVID-19-Related Sales Drive Lilly’s Strong Q4 Performance

Jan 29 2021

• By Joseph Haas

Lilly — Lilly's revenues got a big boost from bamlanivimab for COVID-19

Related Content

Lilly’s Neutralizing Antibodies Reduce Risk Of Serious COVID-19 Outcomes By 70%

Jan 26 2021

An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed

Jan 13 2021

Lilly Sees Positive Results With Next-Gen Alzheimer’s Drug Donanemab

Jan 12 2021

Coronavirus Update: Lilly’s Antibody EUA Adds To ‘Turnaround’ Hopes On Pandemic

Nov 10 2020

Lilly’s 2021 Double-Digit Growth Comes From COVID-19 Drugs, New Products

Dec 16 2020

Lilly's Tirzepatide Hits On Phase III, But Poised To Face A Crowded Diabetes Market

Dec 09 2020

Loxo Lays Out Plans For BTK Inhibitor LOXO-305 In CLL

Dec 07 2020

Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Dec 05 2019

Related Companies

Eli Lilly and Company

AbCellera Biologics Inc.

Shanghai Junshi Biosciences Co., Ltd.

Additional Topics

Sales & Earnings Business Strategies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.